NU-CEFUROXIME TABLET

País: Canadà

Idioma: anglès

Font: Health Canada

Compra'l ara

Descargar Fitxa tècnica (SPC)
04-11-2009

ingredients actius:

CEFUROXIME (CEFUROXIME AXETIL)

Disponible des:

NU-PHARM INC

Codi ATC:

J01DC02

Designació comuna internacional (DCI):

CEFUROXIME

Dosis:

500MG

formulario farmacéutico:

TABLET

Composición:

CEFUROXIME (CEFUROXIME AXETIL) 500MG

Vía de administración:

ORAL

Unidades en paquete:

60/100/500

tipo de receta:

Prescription

Área terapéutica:

SECOND GENERATION CEPHALOSPORINS

Resumen del producto:

Active ingredient group (AIG) number: 0122448002; AHFS:

Estat d'Autorització:

CANCELLED (UNRETURNED ANNUAL)

Data d'autorització:

2018-03-28

Fitxa tècnica

                                Page 1 of 26
PRODUCT MONOGRAPH
PR
NU-CEFUROXIME
CEFUROXIME AXETIL TABLETS
250 MG AND 500 MG CEFUROXIME/TABLET
NU-PHARM STANDARD
ANTIBIOTIC
NU-PHARM INC.
DATE OF PREPARATION:
50 MURAL ST., UNITS 1 & 2
OCTOBER 20, 2009
RICHMOND HILL, ONTARIO
L4B 1E4
CONTROL#: 133377
Page 2 of 26
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................3
SUMMARY PRODUCT
INFORMATION.................................................................................3
INDICATIONS AND CLINICAL
USE.......................................................................................3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND
PRECAUTIONS.........................................................................................4
ADVERSE REACTIONS
.........................................................................................................5
DRUG
INTERACTIONS..........................................................................................................6
DOSAGE AND
ADMINISTRATION.........................................................................................6
OVERDOSAGE.......................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................7
STORAGE AND STABILITY
...................................................................................................7
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................7
PART II: SCIENTIFIC
INFORMATION.......................................................................................9
PHARMACEUTICAL
INFORMATION.....................................................................................9
CLINICAL
TRIALS.......................................................................................................
                                
                                Llegiu el document complet
                                
                            

Cerqueu alertes relacionades amb aquest producte

Veure l'historial de documents